Addison Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Addison Capital's XBI Position: Q1 2026 in Review
Addison Capital increased its State Street SPDR S&P Biotech ETF (XBI) stake by 198% in Q1 2026, buying an estimated $3.16M and bringing the position to 38,112 shares worth $4.87M. The position accounts for 0.87% of the portfolio, ranked #31.
Addison Capital first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Addison Capital held 38,112 shares of State Street SPDR S&P Biotech ETF worth $4.87M as of Q1 2026.
- Addison Capital bought 25,319 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $3.16M.
- State Street SPDR S&P Biotech ETF made up 0.87% of Addison Capital's portfolio in Q1 2026, its #31 holding.
- Addison Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
- 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Addison Capital's 13F filing for Q1 2026, filed 29 Apr 2026.